These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21452321)

  • 1. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use.
    Prieto-Alhambra D; Javaid MK; Judge A; Maskell J; Kiran A; de Vries F; Cooper C; Arden NK
    Arthritis Rheum; 2011 Apr; 63(4):992-1001. PubMed ID: 21452321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis.
    Prieto-Alhambra D; Javaid MK; Judge A; Maskell J; Kiran A; Cooper C; Arden NK
    Osteoporos Int; 2011 May; 22(5):1555-71. PubMed ID: 20694456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
    Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
    Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort.
    Prieto-Alhambra D; Lalmohamed A; Abrahamsen B; Arden NK; de Boer A; Vestergaard P; de Vries F
    Arthritis Rheumatol; 2014 Nov; 66(11):3233-40. PubMed ID: 25047677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study.
    Hung CC; Wang CY; Fu SH; Yang RS; Hsiao FY
    Arch Osteoporos; 2018 Oct; 13(1):107. PubMed ID: 30306268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study.
    Prieto-Alhambra D; Javaid MK; Judge A; Murray D; Carr A; Cooper C; Arden NK
    BMJ; 2011 Dec; 343():d7222. PubMed ID: 22147909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of radiographic hip osteoarthritis: A retrospective cohort study with 11-28 years of followup.
    Franklin J; Ingvarsson T; Englund M; Ingimarsson O; Robertsson O; Lohmander LS
    Arthritis Care Res (Hoboken); 2011 May; 63(5):689-95. PubMed ID: 21557524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults.
    Zullo AR; Sorial MN; Lee Y; Lary CW; Kiel DP; Berry SD
    J Am Geriatr Soc; 2020 Feb; 68(2):256-260. PubMed ID: 31580488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bisphosphonates on knee replacement surgery.
    Neogi T; Li S; Peloquin C; Misra D; Zhang Y
    Ann Rheum Dis; 2018 Jan; 77(1):92-97. PubMed ID: 28988204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate Use After Hip Fracture in Older Adults: A Nationwide Retrospective Cohort Study.
    Nordström P; Toots A; Gustafson Y; Thorngren KG; Hommel A; Nordström A
    J Am Med Dir Assoc; 2017 Jun; 18(6):515-521. PubMed ID: 28238673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
    de Vries F; Cooper AL; Cockle SM; van Staa TP; Cooper C
    Osteoporos Int; 2009 Dec; 20(12):1989-98. PubMed ID: 19333676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.
    Tzeng HE; Muo CH; Chen HT; Hwang WL; Hsu HC; Tsai CH
    BMC Musculoskelet Disord; 2015 May; 16():123. PubMed ID: 25989902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.